Learn from the best in healthcare. We present you with real-time developments and actionable strategies. Register to ask your immediate questions and to access our slides.
Avalere’s data analytics and market access experts will be joined by Jeff Patton, MD and CEO of OneOncology, to explore critical issues and considerations for life sciences stakeholders following the pandemic.
Avalere experts examined the changing oncology landscape amid the COVID-19 pandemic.
Join Avalere’s panel of data analytics, market access, and policy experts for a discussion on the potential for federal drug pricing reform in Congress or via administrative action.
Join leading experts from Avalere Health and Tivity Health to learn more about new analyses detailing seniors’ lived experiences with the COVID-19 pandemic, including recent survey data on the vaccine rollout nationwide.
Join Avalere’s panel of market access and policy experts to learn about the shifting insurance coverage landscape and how these trends impact manufacturers, payers, policymakers, and providers.
Join Avalere’s panel of policy, public health, and regulatory experts to learn about the challenges, opportunities, and key milestones to watch.
The accelerated changes and increased uncertainties in healthcare brought on by the COVID-19 pandemic will continue into 2021, and its impacts are likely to shape healthcare for years to come. While prevalent uncertainty is a given, the broad outline of a new era is already emerging. More than ever, careful examination of healthcare stakeholder’s business models, policy developments, and data will be essential to arrive at accurate assessments of the future state. Our experts engaged in a live discussion covering critical issues facing healthcare leaders and strategies for clearing the path.
For even deeper coverage, download the 2021 Healthcare Industry Outlook document below.
Avalere experts discussed how the 2020 election is influencing the future of healthcare.
Avalere experts took a closer look at emerging oncology trends, innovative approaches to payment and delivery, and what these changes will mean for patient access.
Join Avalere experts for Part 1 of our Market Access Enablement Strategies webinar series to learn about how life sciences companies are pivoting with pre-/post-new product launch strategies, including differential investments to inform market access execution.
Join Avalere experts for Part 2 of our Market Access Enablement Strategies webinar series to learn about the policy changes and market factors that could impact the future relationships between manufacturers, health plans, and pharmacy benefit managers.
Avalere’s 2020 Election series started with our experts covering the current state of play in the 2020 election and the role of healthcare between now and November.
Avalere experts discussed the marketplace for COVID-19 vaccines and therapeutics, including key decision points for regulatory pathways, pricing, and distribution scenarios for optimal US and EX-US market access.
Avalere experts explored the future role of telehealth and how organizations can help shape and take advantage of its increased utilization.
Avalere experts discussed new data analytics and health economics and outcomes research approaches for evaluating key value-based topics in healthcare, including novel curative therapy affordability and access, alternative payment models, and the increasingly important role of real-world evidence in healthcare decision-making.
Avalere experts discussed the key issues and considerations for the healthcare industry as millions of Americans shift in and out of new sources of coverage.
Avalere experts examined evolving stakeholder-specific considerations for reshaping how patients with autoimmune conditions receive care during and after the COVID-19 pandemic.
Experts from Avalere and the National Patient Advocate Foundation (NPAF) discussed the value of shared decision-making (SDM) and preparing patients and families for navigating their care journeys.
Our panel of experts engaged in an in-depth discussion of the rapidly evolving regulatory environment surrounding COVID-19 testing and treatment and the strategic, financial, and operational challenges this disease presents for health insurers.
Just because we can’t meet at sPCMA doesn’t mean we can’t discuss what’s next for Medicare Part D.